Literature DB >> 1327396

Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.

R Seth1, A L Jennings, J Bindman, J Phillips, K Bergmann.   

Abstract

Eight cases of resistant recurrent depression were treated with a combination of nortriptyline and a new serotonin reuptake inhibitor, with or without concurrent lithium therapy. Significant improvement was seen in all patients where other drug regimes and ECT had been ineffective. No adverse reactions occurred in any of our patients, seven of whom were elderly. The combination treatment was more effective than individual therapies alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327396     DOI: 10.1192/bjp.161.4.562

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

2.  Effects of milnacipran in animal models of anxiety and memory.

Authors:  Vânia K M Moojen; Márcio Rodrigo Martins; Adalisa Reinke; Gustavo Feier; Fabiano R Agostinho; Edson M Cechin; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

3.  An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.

Authors:  Jeremy Barowsky; Thomas L Schwartz
Journal:  Psychiatry (Edgmont)       Date:  2006-07

4.  Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?

Authors:  P McManus; A Mant; P Mitchell; D Birkett; J Dudley
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 5.  Psychotropic drugs, aging and community care.

Authors:  M Philpot; A Puranik
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

6.  Antioxidant-like effects and protective action of transcranial magnetic stimulation in depression caused by olfactory bulbectomy.

Authors:  Inmaculada Tasset; René Drucker-Colín; José Peña; Ignacio Jimena; Pedro Montilla; Francisco Javier Medina; Isaac Túnez
Journal:  Neurochem Res       Date:  2010-04-29       Impact factor: 3.996

7.  A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Authors:  Frances R Levin; John Mariani; Daniel J Brooks; Martina Pavlicova; Edward V Nunes; Vito Agosti; Adam Bisaga; Maria A Sullivan; Kenneth M Carpenter
Journal:  Addiction       Date:  2013-03-21       Impact factor: 6.526

8.  Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Authors:  Antonio Tundo; Rocco de Filippis; Luca Proietti
Journal:  World J Psychiatry       Date:  2015-09-22

Review 9.  Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.

Authors:  I Schweitzer; V Tuckwell
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

10.  Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects.

Authors:  Stephan Chalon; Alvaro Pereira; Eric Lainey; François Vandenhende; John G Watkin; Luc Staner; Luc-André Granier
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.